Top

World Journal of Urology

Published in:

Open Access 01-11-2020 | Benign Prostatic Hypertrophy | Original Article

The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia

Authors: Y. Wu, Y. Ding, Q. F. Cao, S. B. Qian, C. Wang, H. Q. Duan, J. Gu, H. B. Shen

Published in: World Journal of Urology | Issue 11/2020

Abstract

Purpose

Increasing evidence shows that many metabolic factors are involved in the progression of benign prostatic hyperplasia (BPH). We aimed to assess the relationship between the status of glucose homeostasis and prostate size in aging Chinese males undergoing transurethral resection of the prostate (TURP) for BPH.

Methods

A total of 1006 medical records of BPH patients undergoing TURP were reviewed. Prostate size was measured by transrectal ultrasound. Annual total prostate (TP) and transitional zone (TZ) growth rates were calculated. According to the American Diabetes Association criteria, the patients were categorized as normoglycemic, prediabetic, or diabetic. Levels of glucose homeostasis and other variables were considered independent variables in an effort to evaluate any potential correlations using non-adjusted and multivariate-adjusted regression models.

Results

A total of 659 individuals were included in the study. BPH patients < 70 years old and ≥ 70 years old in the normoglycemic group had a stable prostate growth rate. The change in prostate size in those younger than 70 years, however, was faster in the prediabetic and diabetic group. Further analysis revealed that abnormal glucose homeostasis was positively correlated with prostate size. In those younger than 70 years, compared with the normal glucose group, the adjusted odds ratio (OR) for TP and TZ enlargement in the prediabetic group was 2.27 (95%CI 1.29–4.00) and 3.19 (95%CI 1.78–5.72), respectively, and the adjusted ORs were 4.74 (95%CI 2.18–10.30) and 6.16 (95%CI 2.70–14.06), respectively, for men with diabetes. However there was no significant difference among men aged ≥ 70 years.

Conclusions

Among patients undergoing TURP, the prostate volume and growth rate were affected by different status of glucose homeostasis. Hyperglycemia may play an important role in prostate growth.

Available only for authorised users

Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA (2006) Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91(7):2562–2568. https://doi.org/10.1210/jc.2005-2799

De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61(3):560–570. https://doi.org/10.1016/j.eururo.2011.11.013

Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M, Waldstreicher J (2000) Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 163(1):13–20. https://doi.org/10.1016/s0022-5347(05)67962-1

Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175(4):1422–1427. https://doi.org/10.1016/s0022-5347(05)00708-1

Qu X, Huang Z, Meng X, Zhang X, Dong L, Zhao X (2014) Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients. Int Urol Nephrol 46(3):499–504. https://doi.org/10.1007/s11255-013-0555-3

Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D (1998) Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1(3):157–162. https://doi.org/10.1038/sj.pcan.4500221

ADA (2017) 2. Classification and diagnosis of diabetes. Diabetes Care 40 (Suppl 1):S11–S24. doi:10.2337/dc17-S005

Menke A, Casagrande S, Geiss L, Cowie CC (2015) Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. doi:10.1001/jama.2015.10029

Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, Li Y, Zhao Z, Qin X, Jin D, Zhou M, Tang X, Hu Y, Wang L (2017) Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317(24):2515–2523. https://doi.org/10.1001/jama.2017.7596

10.

Lee C, Kozlowski JM, Grayhack JT (1995) Etiology of benign prostatic hyperplasia. Urol Clin North Am 22(2):237–246

11.

Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC (2009) Prostate volume changes over time: results from the Baltimore longitudinal study of aging. J Urol 182(4):1458–1462. https://doi.org/10.1016/j.juro.2009.06.047

12.

Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL (2007) Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men. Prostate 67(16):1816–1824. https://doi.org/10.1002/pros.20663

13.

Cao N, Lu Q, Si J, Wang X, Ni J, Chen L, Gu B, Hu B (2017) The characteristics of the transitional zone in prostate growth with age. Urology 105:136–140. https://doi.org/10.1016/j.urology.2017.03.010

14.

Williams AM, Simon I, Landis PK, Moser C, Christens-Barry W, Carter HB, Metter EJ, Partin AWJ, Jo A (1999) Prostatic growth rate determined from MRI data: age-related longitudinal changes. J Androl 20(4):474–480

15.

Zhang SJ, Qian HN, Zhao Y, Sun K, Wang HQ, Liang GQ, Li FH, Li Z (2013) Relationship between age and prostate size. Asian J Androl 15(1):116–120. https://doi.org/10.1038/aja.2012.127

16.

Nickel JC, Aaron L, Barkin J, Elterman D, Nachabe M, Zorn KC (2018) Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J 12(10):303–312. https://doi.org/10.5489/cuaj.5616

17.

Hammarsten J, Hogstedt B (2001) Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39(2):151–158. https://doi.org/10.1159/000052430

18.

American Diabetes A (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1):S62–69. https://doi.org/10.2337/dc11-S062

19.

Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F (2006) Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 98(5):1038–1042. https://doi.org/10.1111/j.1464-410X.2006.06400.x

20.

Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82(4–5):184–199. https://doi.org/10.1016/j.diff.2011.04.006

21.

Bourke JB, Griffin JP (1966) Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol 38(1):18–23. https://doi.org/10.1111/j.1464-410X.1966.tb09675.x

22.

Ozcan L, Besiroglu H, Dursun M, Polat EC, Otunctemur A, Ozbek E (2017) Comparison of the clinical parameters of benign prostate hyperplasia in diabetic and non diabetic patients. Arch Ital Urol Androl 89(1):26–30. https://doi.org/10.4081/aiua.2017.1.26

23.

Li SH, Yang QF, Zuo PY, Liu YW, Liao YH, Liu CY (2016) Prostate volume growth rate changes over time: results from men 18 to 92 years old in a longitudinal community-based study. J Huazhong Univ Sci Technolog Med Sci 36(6):796–800. https://doi.org/10.1007/s11596-016-1664-x

24.

Arthur R, Moller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Hemelrijck MV (2016) Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med 5(6):1307–1318. https://doi.org/10.1002/cam4.665

25.

Nandeesha H, Koner BC, Dorairajan LN, Sen SK (2006) Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 370(1–2):89–93. https://doi.org/10.1016/j.cca.2006.01.019

26.

Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51 (1):199–203; discussion 204–196. doi:10.1016/j.eururo.2006.05.040

27.

Sampson N, Zenzmaier C, Heitz M, Hermann M, Plas E, Schafer G, Klocker H, Berger P (2013) Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation. Endocrinology 154(8):2586–2599. https://doi.org/10.1210/en.2012-2259

28.

Huang Y, Cai X, Mai W, Li M, Hu Y (2016) Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 355:i5953. https://doi.org/10.1136/bmj.i5953

29.

Wang Z, Olumi AF (2011) Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 82(4–5):261–271. https://doi.org/10.1016/j.diff.2011.04.004

30.

Xu C, Xu Y, Shen Z, Zhou H, Xiao J, Huang T (2018) Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia. Int Urol Nephrol 50(4):611–617. https://doi.org/10.1007/s11255-018-1826-9

Title: The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia
Authors: Y. Wu
Y. Ding
Q. F. Cao
S. B. Qian
C. Wang
H. Q. Duan
J. Gu
H. B. Shen
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Keywords: Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Prediabetes
Transurethral Prostate Resection
Testosterone
Published in: World Journal of Urology / Issue 11/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-020-03084-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2020

Design, implementation, and evaluation of a novel curriculum to teach transurethral resection of the prostate (TURP): a 3-year experience of urology simulation bootcamp course

Recurrent bladder cystitis: who takes the role?

Challenges facing the urologist in low- and middle-income countries

Current perspectives on urolithiasis management in China

Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines

Five compelling UTI questions after kidney transplant